UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Zhejiang Nanobody Technology Center Co., Ltd., established on 2018-06-19, The scope of business includes engaging in technology development in the field of nanobody technology,technical consulting,technology transfer,Technical Services(Do not engage in medical activities);Production of Nanobodies,processing;Alpaca Breeding Services;Processing and management of alpaca peripheral products,Tea product processing and management;Ecotourism Services,Business Management Consulting,brand management,business inquiries,Exhibition display service,account Serive,marketing planning,Organization and planning of public relations activities,Enterprise Marketing Planning.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.

Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybodyâ„¢). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

GlycoTech Corporation focuses on the biological functions and medical applications of glycoconjugates. The company was founded by John Magnani and is headquartered in Gaithersburg, Maryland.

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.